Deciding individual treatment for primary retroperitoneal sarcoma.

Area of Science:

• Oncology
• Surgical Oncology
• Medical Oncology

Background:

• Retroperitoneal sarcomas (RPS) are rare mesenchymal tumors, representing 0.1-0.2% of all malignancies.
• Management is complex, with surgical resection being the primary treatment.
• International collaboration has improved understanding and personalized care, leading to better survival rates.

Purpose of the Study:

• To review the current literature on the management of primary RPS.
• To emphasize a histology-driven approach for personalized treatment strategies.
• To summarize recent advances and future directions in RPS management.

Main Methods:

• Comprehensive literature search of articles published between 1993 and 2023.
• Focus on studies investigating prognostic factors and treatment modalities for RPS.
• Synthesis of findings to highlight recent advances and future research directions.

Main Results:

• RPS management requires a personalized approach due to histological heterogeneity and varying responses to therapy.
• Histology and grade influence recurrence patterns and sensitivity to neoadjuvant treatments.
• Individualized treatment pathways are crucial for optimizing patient outcomes.

Conclusions:

• A histology-driven approach is essential for managing primary RPS.
• Understanding prognostic factors and tailoring treatment based on individual patient characteristics is key.
• Further research into neoadjuvant therapies, including radiotherapy and chemotherapy, will refine individualized treatment strategies.